TEVA vs. ALNY
TEVA (Teva Pharmaceutical Industries Limited) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — TEVA in Drug Manufacturers - Specialty & Generic, ALNY in Biotechnology. Over the past 10 years, TEVA returned -4.15%/yr vs 16.55%/yr for ALNY. At a 0.26 correlation, their price movements are largely independent.
Performance
TEVA vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TEVA achieves a 6.57% return, which is significantly higher than ALNY's -26.53% return. Over the past 10 years, TEVA has underperformed ALNY with an annualized return of -4.15%, while ALNY has yielded a comparatively higher 16.55% annualized return.
TEVA
- 1D
- -2.72%
- 1M
- -6.91%
- YTD
- 6.57%
- 6M
- 17.40%
- 1Y
- 87.17%
- 3Y*
- 65.55%
- 5Y*
- 25.39%
- 10Y*
- -4.15%
ALNY
- 1D
- -3.59%
- 1M
- -0.98%
- YTD
- -26.53%
- 6M
- -32.06%
- 1Y
- -2.88%
- 3Y*
- 15.25%
- 5Y*
- 13.17%
- 10Y*
- 16.55%
TEVA vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | 6.57% | 41.61% | 111.11% | 14.47% | 13.86% | -16.99% | -1.53% | -36.45% | -18.63% | -46.18% |
ALNY Alnylam Pharmaceuticals, Inc. | -26.53% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between TEVA and ALNY is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.38 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 2004 | 0.26 |
The correlation between TEVA and ALNY shifts across timeframes, from 0.26 (5 years) to 0.38 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
TEVA:
$39.21B
ALNY:
$40.38B
TEVA:
$1.34
ALNY:
$4.26
TEVA:
24.87
ALNY:
68.52
TEVA:
2.24
ALNY:
9.23
TEVA:
4.76
ALNY:
37.55
TEVA:
$17.35B
ALNY:
$4.29B
TEVA:
$9.03B
ALNY:
$2.51B
TEVA:
$3.05B
ALNY:
$729.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TEVA vs. ALNY — Risk / Return Rank
TEVA
ALNY
TEVA vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TEVA | ALNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.33 | ||
| Sortino ratioReturn per unit of downside risk | +3.27 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.02 | +0.42 |
| Calmar ratioReturn relative to maximum drawdown | 4.02 | -0.07 | +4.09 |
| Martin ratioReturn relative to average drawdown | 10.94 | -0.12 | +11.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TEVA | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.25 | -0.08 | +2.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.59 | 0.27 | +0.32 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | 0.31 | -0.40 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.32 | -0.01 |
Drawdowns
TEVA vs. ALNY - Drawdown Comparison
The maximum TEVA drawdown since its inception was -90.89%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for TEVA and ALNY.
Loading charts...
Drawdown Indicators
| TEVA | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.89% | -83.58% | -7.31% |
Max Drawdown (1Y)Largest decline over 1 year | -21.79% | -42.01% | +20.22% |
Max Drawdown (3Y)Largest decline over 3 years | -43.70% | -42.01% | -1.69% |
Max Drawdown (5Y)Largest decline over 5 years | -43.70% | -42.46% | -1.24% |
Max Drawdown (10Y)Largest decline over 10 years | -88.41% | -59.95% | -28.46% |
Current DrawdownCurrent decline from peak | -50.84% | -40.52% | -10.32% |
Average DrawdownAverage peak-to-trough decline | -32.00% | -30.59% | -1.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.00% | 23.22% | -15.22% |
Volatility
TEVA vs. ALNY - Volatility Comparison
The current volatility for Teva Pharmaceutical Industries Limited (TEVA) is 9.18%, while Alnylam Pharmaceuticals, Inc. (ALNY) has a volatility of 9.94%. This indicates that TEVA experiences smaller price fluctuations and is considered to be less risky than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TEVA | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.18% | 9.94% | -0.76% |
Volatility (6M)Calculated over the trailing 6-month period | 23.54% | 26.34% | -2.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.97% | 36.87% | +2.10% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.94% | 48.88% | -5.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 47.34% | 53.66% | -6.32% |
Dividends
TEVA vs. ALNY - Dividend Comparison
Neither TEVA nor ALNY has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Financials
TEVA vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TEVA vs. ALNY - Profitability Comparison
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.
Frequently Asked Questions
TEVA and ALNY have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALNY has higher volatility (9.94%) compared to TEVA (9.18%). In terms of maximum drawdown, TEVA dropped -90.89% vs ALNY's -83.58%.
TEVA currently has the higher Sharpe Ratio (2.25 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TEVA and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer